AllSci News
Innovent secures China approval for first domestic IL-23p19 antibody picankibart
China’s National Medical Products Administration (NMPA) issued a first market approval to Innovent Biologics’ Pecondle (picankibart), the country’s first domestically developed IL-23p19…
Novo Nordisk’s amycretin demonstrates best-in-class potential in Phase 2
Novo Nordisk is gaining confidence in its dual GLP-1/amylin agonist pipeline candidate amycretin after the molecule delivered substantial improvements in both glycemic…
Mabwell launches Phase I/II trials for CDH17 ADC
China-based biotech Mabwell is initiating two Phase I/II clinical trials of its CDH17-targeted antibody–drug conjugate (ADC) 7MW4911. The China study (CTR20254163) will…
Mazdutide delivers up to 20% weight loss in Innovent’s Phase 3 trial
Innovent Biologics reported that mazdutide 9 mg, a potential first-in-class dual GCG/GLP-1 receptor agonist, achieved up to 20.1% weight loss in Chinese…
Novo’s Alzheimer’s Hail Mary for semaglutide fails in EVOKE Phase 3 trials
Novo Nordisk A/S disclosed that its bid to expand the repertoire of GLP-1 receptor agonist semaglutide to Alzheimer’s disease (AD) has failed.…
MSD and Kelun’s TROP2 ADC succeeds in Keytruda combo for NSCLC
Merck & Co. partner Sichuan Kelun Biotech Biopharmaceutical announced another Phase 3 success for the TROP2-targeted antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT;…
J&J halts study for tau-targeted Alzheimer’s antibody
Johnson & Johnson (J&J) has discontinued the Phase 2b AuTonomy trial evaluating its tau-targeted monoclonal antibody posdinemab (JNJ-63733657) in early Alzheimer’s disease…
PeproMene showcases breakthrough BAFF-R CAR-T results in CD19-escape B-cell malignancies at ASH 2025
US-based cell therapy developer PeproMene Bio announced that its BAFF‑R‑targeted autologous CAR T candidate, PMB‑CT01, has been selected for two oral presentations at…
Unlocking the Secrets Behind Top Drugs
“The difference between good pharmaceutical investing and great pharmaceutical investing isn’t access to data—it’s the ability to decode the science behind the…
How AERIS AI is Revolutionizing Scientific Research
“The future of research isn’t about reading more papers—it’s about understanding them better, faster, and with complete transparency.” How AERIS AI is…
AllSci Wins Grant to Expand AI Platform
Empowering researchers at every level to test hypotheses, validate findings, and collaborate to advance science AllSci Wins Grant to Expand AI Platform…
AllSci Unveils Revolutionary Scientific Knowledge Platform
As a researcher and publishing executive, I understand the frustrations around peer review, publishing, and recognition. AllSci changes the game by providing…
AllSci Launches AI Development Partner Program
AllSci’s technology transforms how pharmaceutical and biotech companies understand the R&D landscape, improves their research productivity, and helps them differentiate their portfolios…
The AllSci Brief
Systematic R&D and deal news. Daily.